Treatment of FRDA in Huizhou

Friedreich's ataxia (FRDA) is the most common hereditary ataxia, while still a rare disease (1 in 50000). ICD-10 code G11.1. The underlying cause is an autosomal recessive mutation in the FXN gene on chromosome 9q21.11, encoding the mitochondrial protein frataxin. Frataxin deficiency disrupts iron-sulfur metabolism in mitochondria and produces progressive degeneration of the posterior spinal columns, dentate nuclei of the cerebellum, peripheral nerves, and cardiac muscle.

Onset is typically at ages 5–15 (late-onset forms are also known), and the course is progressive: the mean age of losing independent ambulation is about 25 years from onset. There is as yet no disease-modifying therapy that fully stops the disease — in 2023 the FDA approved the first drug (omaveloxolone / Skyclarys), which slows progression; gene and cell therapies are on the horizon. Rehabilitation already today significantly affects quality of life, extends functional capabilities, and preserves independence.

At NeuroLife Huizhou the program is built around the disease stage and is run regularly, two courses per year, in parallel with the core treatment. The program combines several streams:

• Coordination training — exercises for movement timing, accuracy, and smoothness (critically important in ataxia);
• Balance therapy — stabilometric platforms, exercises on unstable surfaces, proprioceptive stimulation;
• Occupational therapy — selecting assistive devices (special walkers, stabilizers, weighted utensils);
• Therapeutic exercise and physiotherapy — preserving muscle mass and joint mobility, massage;
• Orthopedic support — a custom orthosis and posture work for scoliosis, and biomechanical insoles for pes cavus;
• Gentle TCM approaches to support the heart — acupuncture at cardiac points, lymphatic drainage massage, herbal blends.

The TCM component requires special attention: hypertrophic cardiomyopathy develops in about 40% of patients and remains the main cause of complications. Workload intensity and cardiac work are therefore coordinated with the pediatric cardiologist (annual echocardiography, ECG monitoring) and the endocrinologist (diabetes risk), and the methods complement one another and are reviewed over the course of the program.